In symptomatic patients, the presence of anti-EMA or anti TGT is highly predictive 97% to100% of histological changes compatible with CD 42. Figure 3.
En pacientes sintomáticos, la presencia de anti-EMA o anti-tGT son altamente predictivos 97-100% de cambios histológicos compatibles con EC 42.